KymaThera Raises $80M Series B to Advance Precision Medicines for Genetically Defined Diseases

San Diego Biotech Secures Series B Funding

KymaThera, a San Diego-based biotechnology company, has raised $80 million in Series B funding. The round was led by Alta Partners, with participation from Venrock, Foresite Capital, and J. Wood Capital.

What KymaThera Does

KymaThera develops precision medicines for genetically defined diseases. The company applies a proprietary structure-based drug design platform, built on decades of drug discovery experience that includes multiple approved medicines, to create differentiated small-molecule therapeutics.

Lead Program

KymaThera's lead program, K-1728, is an internally discovered, oral pan-mutant selective PI3Kalpha inhibitor. It is being advanced into Phase 1 trials for PI3Kalpha-mutant cancers and PI3Kalpha-driven vascular malformations. The company also has earlier-stage discovery programs against additional validated disease targets.

Pipeline and Approach

The focus on genetically defined diseases allows KymaThera to target patient populations with specific mutations, potentially increasing the probability of clinical success. The structure-based drug design platform is central to the company's ability to generate differentiated small molecules.

Use of Funds

While the company has not detailed exact allocation, Series B funding at this stage typically supports clinical development, including Phase 1 trials for lead programs, as well as advancement of earlier-stage discovery programs and general corporate purposes.

Acquisition Angle

For acquirers in biotech and pharmaceuticals, KymaThera represents a clinical-stage asset with a lead program entering Phase 1, a proprietary discovery platform, and a team with a track record of approved medicines. The focus on PI3Kalpha-mutant cancers and vascular malformations addresses areas of high unmet need. As the company advances K-1728 through clinical trials, it could become an attractive target for larger oncology-focused players seeking to bolster their precision medicine pipelines.

Summary

• Company: KymaThera
• HQ: San Diego, California
• Stage: Series B
• Amount: $80,000,000
• Lead Investor: Alta Partners
• Other Investors: Venrock, Foresite Capital, J. Wood Capital
• Focus: Precision medicines for genetically defined diseases using a proprietary structure-based drug design platform
• Lead Program: K-1728, an oral pan-mutant selective PI3Kalpha inhibitor, entering Phase 1 for PI3Kalpha-mutant cancers and PI3Kalpha-driven vascular malformations
• Pipeline: Earlier-stage discovery programs against additional validated disease targets